Biotech Values

[DewDiligence]

Selected slides from GENR’s Squalamine program:

Below are eight slides that I find especially noteworthy. (The complete set of slides can be found at: http://www.genaera.com/AMD_4%20Mo_Slides_10.07.03.pdf ):

Slide 17: Overview of competing therapies (Macugen, Lucentis, Squalamine):




Slide 18: Comparative efficacy at 2-3 months of the same three drugs:




Slides 29-31: The awesome market potential of drugs to treat AMD:




Slide 40: Squalamine’s mechanism of action:




Slide 50: Squalamine efficacy at 4 months:




Slide 52: Efficacy at 4 months stratified by dose. This is an especially important slide because it suggests that the 50mg/m2 dose did not work appreciably better than the 25mg/m2 dose:



[End]